Filtered By:
Specialty: Drugs & Pharmacology
Procedure: Dialysis
Therapy: Dialysis

This page shows you your search results in order of date.

Order by Relevance | Date

Total 16 results found since Jan 2013.

Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme
ConclusionGlobally, CKD carries a significant economic burden, which increases substantially with increasing disease severity. We identified significant gaps in published costs and inconsistent costing definitions. Cost-effective interventions that target primary prevention and disease progression are essential to reduce CKD burden. Our results can be used to guide cost collection and facilitate better comparisons across countries/regions to inform healthcare policy.
Source: Advances in Therapy - July 26, 2023 Category: Drugs & Pharmacology Source Type: research

Effect of sodium bicarbonate on cardiovascular outcome and mortality in patients with advanced chronic kidney disease
Conclusion: The cohort study found that in real world practice, among patients with advanced CKD stage V, use of sodium bicarbonate was associated with similar risk of dialysis compared with non-users, Nonetheless, use of sodium bicarbonate was associated with significantly lower rate of MACE and mortality. The study results reinforced the benefits of sodium bicarbonate therapy in the expanding CKD population. Further prospective studies are needed to confirm these findings.
Source: Frontiers in Pharmacology - May 11, 2023 Category: Drugs & Pharmacology Source Type: research

Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
ConclusionThere was no evidence of increased risk of cardiovascular events or mortality with roxadustat compared with ESA in patients with anemia who have NDD or ID-DD CKD. Although TEAEs occurred commonly in both the roxadustat and ESA groups, patients infrequently discontinued the study drug because of an adverse event.Clinical Trial Registration NumbersDOLOMITES, 1517-CL-0610 [NCT02021318]; HIMALAYAS, FGCL-4592-063 [NCT02052310]; SIERRAS, FGCL-4592-064 [NCT02273726]; and ROCKIES, D5740C00002 [NCT02174731].
Source: Advances in Therapy - February 7, 2023 Category: Drugs & Pharmacology Source Type: research

Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
ConclusionRoxadustat improved hemoglobin similarly to ESA while demonstrating comparable cardiovascular and overall safety profiles in a wide spectrum of dialysis-dependent patients with anemia of CKD. Roxadustat represents an oral alternative to ESAs for achieving a target hemoglobin for anemia of CKD in dialysis-dependent patients.
Source: Advances in Therapy - September 14, 2021 Category: Drugs & Pharmacology Source Type: research

Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis
ConclusionsIn pooled, analyzed randomized controlled trials and observational studies, DOACs were associated with better efficacy in early CKD, as well as similar efficacy and safety outcomes to warfarin in patients with CKD stages 4 –5 or dialysis patients. The results of patients with CKD stages 4–5 and dialysis patients were from observational studies. Well-designed randomized controlled trials focused on DOAC use in patients with CKD and dialysis patients are needed.PROSPERO register number: CRD42020150599, 6 February, 2020.
Source: Clinical Drug Investigation - March 11, 2021 Category: Drugs & Pharmacology Source Type: research

Clinical Outcomes and Healthcare Resource Utilization in a Real-World Population Reflecting the DAPA-CKD Trial Participants
ConclusionThe significant adverse renal and cardiovascular outcomes observed, particularly in the DAPA-CKD-like cohort, represent a substantial burden resulting in increased mortality, HCRU and costs, demonstrating the need for additional treatment options.
Source: Advances in Therapy - January 20, 2021 Category: Drugs & Pharmacology Source Type: research

Oral Cannabidiol Prevents Allodynia and Neurological Dysfunctions in a Mouse Model of Mild Traumatic Brain Injury
Conclusion In conclusion, our data demonstrate that mTBI causes late sensorial affective/cognitive deficiencies linked to altered neurotransmitter release at cortical level. Moreover, we showed that chronic CBD treatment reduces behavioral dysfunctions by restoring at least in part cortical biochemical processes. Taken together, our results suggest that CBD could represent a novel approach for the management of neuropsychiatric disorders associated with TBI. Author Contributions CB, LL, and RR conceived and designed the experiments. CB, MI, SB, FR, RI, and RM performed the experiments. GP, LS, SP, RR, LL, and IM analyze...
Source: Frontiers in Pharmacology - April 15, 2019 Category: Drugs & Pharmacology Source Type: research

Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease.
Conclusion and Relevance: Patients with advanced CKD taking apixaban had similar bleeding rates at 3 months compared with those taking warfarin. However, those who continued therapy had higher major bleeding rates with warfarin between 6 and 12 months. This study provides knowledge on the effects of a direct oral anticoagulant in a population that was excluded from all major trials. PMID: 29871510 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - June 1, 2018 Category: Drugs & Pharmacology Authors: Schafer JH, Casey AL, Dupre KA, Staubes BA Tags: Ann Pharmacother Source Type: research

Transdermal estradiol for the management of refractory uremic bleeding.
CONCLUSION: Patients who are refractory to routine interventions for uremic bleeding may benefit from transdermal estrogen despite the limited data. Extended therapy with low-dose transdermal estrogen (≤50 μg daily) may provide a hemostatic benefit that outweighs thrombotic risk. PMID: 29691259 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - April 25, 2018 Category: Drugs & Pharmacology Authors: Gonzalez J, Bryant S, Hermes-DeSantis ER Tags: Am J Health Syst Pharm Source Type: research

Effects of cilostazol and renin-angiotensin system (RAS) blockers on the renal disease progression of Korean patients: a retrospective cohort study
Conclusion Treatment with cilostazol plus ACEI or ARB was observed to prevent worsening of renal progression in patients in the stages 1 –2.
Source: International Journal of Clinical Pharmacy - December 27, 2017 Category: Drugs & Pharmacology Source Type: research

Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment
ConclusionApixaban appears to be a reasonable alternative to warfarin in patients with severe renal impairment.This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - December 31, 2016 Category: Drugs & Pharmacology Authors: Brooke E. Stanton, Naomi S. Barasch, Katie B. Tellor Tags: Original Research Article Source Type: research

The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease
Abstract Chronic kidney disease (CKD) anemia treatment was revolutionized in the late 1980s with the introduction of recombinant human erythropoietin. This and related erythropoiesis-stimulating agents (ESAs) greatly benefited patients by decreasing debilitating symptoms, improving their quality of life, and freeing them from dependence on blood transfusions with their associated complications such as infections, sensitization impeding transplantation, and secondary iron overload. However, even in the initial studies, untoward effects were noted in patients receiving ESAs, including worsening hypertension, seizure...
Source: Clinical Drug Investigation - February 19, 2016 Category: Drugs & Pharmacology Source Type: research

The problem of atrial fibrillation in patients with chronic kidney disease.
Abstract Chronic kidney disease (CKD) is associated with the risk of multiple life-threatening complications such as: progression to chronic renal failure and cardiovascular disease including coronary heart disease, heart failure and peripheral arterial disease. Also, atrial fibrillation (AF) is common in this group of patients. Factors contributing to the occurrence of AF in patients undergoing dialysis include: age, presence of coronary heart disease, echocardiographic abnormalities (low ejection fraction, atrial enlargement, valvular calcification, left ventricular hypertrophy), heart failure, chronic obstructi...
Source: Current Vascular Pharmacology - January 15, 2016 Category: Drugs & Pharmacology Authors: Franczyk B, Gluba-Brzózka A, Ciałkowska-Rysz A, Banach M, Rysz J Tags: Curr Vasc Pharmacol Source Type: research

Coronary Revascularization in Chronic and End-Stage Renal Disease: A Systematic Review and Meta-analysis
Patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) on dialysis have an increased risk for cardiovascular mortality and morbidity secondary to occlusive coronary artery disease. Optimal revascularization strategy is unclear in this high-risk population. We have performed a meta-analysis to compare coronary artery bypass grafting (CABG) versus percutaneous coronary intervention (PCI) in patients with ESRD and CKD. We searched PubMed, Ovid, MEDLINE, CINAHL, and EMBASE (1980–2013) and found 17 trials (N = 33,584) in the ESRD arm and 6 studies (n = 15,493) in the CKD arm. Two investigators independe...
Source: American Journal of Therapeutics - January 1, 2016 Category: Drugs & Pharmacology Tags: Original Articles Source Type: research

Valacyclovir and Acyclovir Neurotoxicity With Status Epilepticus
We present the case of a 52-year-old man with hypertension, diastolic congestive heart failure, end-stage renal disease on hemodialysis 3 times a week and a remote history of a hemorrhagic stroke who presented to the emergency department with a vesicular rash on his left arm. The rash was observed to be in a dermatomal distribution, and a diagnosis of herpes zoster was made. The patient was discharged home on valacyclovir 1 g 3 times a day for a duration of 7 days. The patient took 2 doses of valacyclovir before presenting to the hospital again with irritability and hallucinations. Over the next several days, the patient's...
Source: American Journal of Therapeutics - January 1, 2016 Category: Drugs & Pharmacology Tags: Case Reports Source Type: research